424870 fundamentals

Immuneoncia Therapeutics, Inc. engages in the development of antibody-based immunotherapy oncology. It operates through the following divisions: IMC-001 (PD-L1), IMC-002 (CD47), IMC-201 (CD47xPD-L1), and IMC-202 (PD-L1xTIGIT). The IMC-001 division is a fully human monoclonal antibody of the IgG1 type that targets PD-L1 and is an immunotherapy for cancer. The IMC-002 division focuses on human monoclonal antibody of the IgG4 type targeting human CD47. The IMC-201 division refers to bispecific antibody with Morrison Format on an IgG1 backbone developed using IMC-001 and IMC-002 as parent antibodies. The IMC-202 division focuses on dual antibody currently under joint development with Yuhan-Yanghaeng. The company was founded on September 1, 2016 and is headquartered in Yongin-si, South Korea.